The Immunology of Hormone Receptor Positive Breast Cancer

by Jonathan Goldberg, Ricardo G. Pastorello, Ricardo G. Pastorello, Tuulia Vallius, Janae Davis, Janae Davis, Yvonne Xiaoyong Cui, Judith Agudo, Judith Agudo, Adrienne G. Waks, Tanya Keenan, Sandra S. McAllister, Sandra S. McAllister, Sandra S. McAllister, Sara M. Tolaney, Elizabeth A. Mittendorf, Elizabeth A. Mittendorf, Elizabeth A. Mittendorf, Elizabeth A. Mittendorf, Jennifer L. Guerriero, Jennifer L. Guerriero, Jennifer L. Guerriero, Jennifer L. Guerriero
Published 2021-05-01

Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiolo...

by Jun Wang, Elizabeth A Mittendorf, Aysegul A Sahin, Min Yi, Abigail Caudle, Kelly K Hunt, Yun Wu
Published 2014-01-01

Metabolic abnormalities and survival among patients with non-metastatic breast cancer

by Alexa S. Zimbalist, Bette J. Caan, Wendy Y. Chen, Elizabeth A. Mittendorf, Deborah A. R. Dillon, Charles Quesenberry, Elizabeth M. Cespedes Feliciano
Published 2022-12-01

Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer

by Christina A. Hartl, Adrian Bertschi, Regina Bou Puerto, Carolin Andresen, Emily M. Cheney, Elizabeth A. Mittendorf, Jennifer L. Guerriero, Michael S. Goldberg
Published 2019-07-01

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

by Paolo Tarantino, Chiara Corti, Peter Schmid, Javier Cortes, Elizabeth A. Mittendorf, Hope Rugo, Sara M. Tolaney, Giampaolo Bianchini, Fabrice Andrè, Giuseppe Curigliano
Published 2022-02-01

Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021

by Elizabeth M. Burton, Rodabe N. Amaria, Tina Cascone, Myriam Chalabi, Neil D. Gross, Elizabeth A. Mittendorf, Richard A. Scolyer, Padmanee Sharma, Paolo A. Ascierto
Published 2022-06-01

Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.

by Yu Ren, Dalliah M Black, Elizabeth A Mittendorf, Peijun Liu, Xu Li, Xianglin L Du, Jianjun He, Jin Yang, Kelly K Hunt, Min Yi
Published 2014-01-01

Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer

by Jessica Castrillon Lal, Madeline G. Townsend, Anita K. Mehta, Madisson Oliwa, Eric Miller, Alaba Sotayo, Emily Cheney, Elizabeth A. Mittendorf, Anthony Letai, Jennifer L. Guerriero
Published 2021-08-01

Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer

by Carlos H. Barrios, Shigehira Saji, Nadia Harbeck, Hong Zhang, Kyung H. Jung, Sheetal Patel, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Stephen Y. Chui, Elizabeth A. Mittendorf
Published 2022-09-01

1485 Characterization of the hormone receptor-positive breast tumor microenvironment using single cell transcriptomics and multi-plex immunofluorescence

by Elizabeth A Mittendorf, Sandro Santagata, Jennifer L Guerriero, Jonathan Goldberg, Peter K Sorger, Kelly F Zheng, Daniel E Michaud, Kenichi Shimada, Cheryl Gu, Yvonne X Cui, Esther R Ogayo
Published 2023-11-01

Inequities in referrals to a breast cancer risk assessment and prevention clinic: a mixed methods study

by Claire B. King, Brittany L. Bychkovsky, Erica T. Warner, Tari A. King, Rachel A. Freedman, Elizabeth A. Mittendorf, Fisher Katlin, Anna Revette, Danielle M. Crookes, Neil Maniar, Lydia E. Pace
Published 2023-08-01

Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine

by Junhua Mai, Zhaoqi Li, Xiaojun Xia, Jingxin Zhang, Jun Li, Haoran Liu, Jianliang Shen, Maricela Ramirez, Feng Li, Zheng Li, Kenji Yokoi, Xuewu Liu, Elizabeth A. Mittendorf, Mauro Ferrari, Haifa Shen
Published 2021-06-01

Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer

by Sonia Pernas, Jennifer L. Guerriero, Sergey Naumenko, Shom Goel, Meredith M. Regan, Jiani Hu, Beth T. Harrison, Filipa Lynce, Nancy U. Lin, Ann Partridge, Aki Morikawa, John Hutchinson, Elizabeth A. Mittendorf, Artem Sokolov, Beth Overmoyer
Published 2022-07-01

896 Characterizing macrophage heterogeneity in HR+/HER2- metastatic breast cancer reveals novel mechanisms of resistance

by Sara M Tolaney, Tianyu Li, Elizabeth A Mittendorf, Sandro Santagata, Jennifer L Guerriero, Nabihah Tayob, Peter K Sorger, Madeline G Townsend, Kelly F Zheng, Kenichi Shimada, Molly DiLullo, Eileen Wrabel, Tanya Keenan, Romualdo Barroso-Sousa
Published 2023-11-01

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer

by Sara M Tolaney, Tianyu Li, Edward T Richardson, Judith Agudo, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Adrienne G Waks, Tanya E Keenan, Nabihah Tayob, Gerburg M Wulf, Victoria Attaya, Leilani Anderson, Ian E Krop, Eliezer M Van Allen
Published 2022-10-01

Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

by Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A. Mittendorf, Tari A. King, Anna Weiss, Ann H. Partridge, Brittany L. Bychkovsky, Giuseppe Curigliano, Nabihah Tayob, Nancy U. Lin, Judy E. Garber, Sara M. Tolaney, Filipa Lynce
Published 2024-04-01

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

by Romualdo Barroso-Sousa, Tanya E. Keenan, Tianyu Li, Nabihah Tayob, Lorenzo Trippa, Ricardo G. Pastorello, Edward T. Richardson III, Deborah Dillon, Zohreh Amoozgar, Beth Overmoyer, Stuart J. Schnitt, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer Van Allen, Dan G. Duda, Sara M. Tolaney
Published 2021-08-01

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

by Sara M Tolaney, Leisha A Emens, Mary L Disis, David B Page, Heather L McArthur, Ashley Cimino-Mathews, Sylvia Adams, Elizabeth A Mittendorf, Rita Nanda, Hope S Rugo, Margaret E Gatti-Mays, Krista M Rubin, Alice Y Ho, Kevin Kalinsky, Hatem Soliman, Patricia A Spears, Jennifer K Litton
Published 2021-08-01

Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target

by Maliha Khan, Selena Carmona, Pariya Sukhumalchandra, Jason Roszik, Jason Roszik, Anne Philips, Alexander A. Perakis, Celine Kerros, Mao Zhang, Na Qiao, Lisa S. St. John, Madhushree Zope, Jonathan Goldberg, Mariam Qazilbash, Haroon Jakher, Karen Clise-Dwyer, Yihua Qiu, Elizabeth A. Mittendorf, Jeffrey J. Molldrem, Steven M. Kornblau, Gheath Alatrash
Published 2018-01-01

Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling

by Joseph D Butner, Geoffrey V Martin, Zhihui Wang, Bruna Corradetti, Mauro Ferrari, Nestor Esnaola, Caroline Chung, David S Hong, James W Welsh, Naomi Hasegawa, Elizabeth A Mittendorf, Steven A Curley, Shu-Hsia Chen, Ping-Ying Pan, Steven K Libutti, Shridar Ganesan, Richard L Sidman, Renata Pasqualini, Wadih Arap, Eugene J Koay, Vittorio Cristini
Published 2021-11-01